Market Minds Advisory
Ophthalmic Combination Product Market

Ophthalmic Combination Product Market: Sustained-Release Implants Replace Monthly Injections

Retina and glaucoma specialists are adopting refillable port delivery systems and bioerodible implants that replace monthly injections with procedures spaced months apart, converting chronic disease management into a durable device-based treatment relationship.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$1.8BMarket Size 2025
2036 FORECAST VALUE$7.2BBase Case , 2026 to 2036
CAGR 2026 TO 203613.5 %Bull 15.0% / Bear 12.0%
INCREMENTAL OPPORTUNITY$5.2BNet 10- year value creation
EXPANSION MULTIPLE3.55x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Ophthalmic combination products are converting chronic retina and glaucoma management from monthly injection visits into durable, device-based treatment relationships. Port delivery systems are capturing that shift fastest across nearly every specialty practice type tracked. Reimbursement recognition is now the pace-setter rather than clinical evidence alone.
Port delivery systems lead every other category on growth as retina specialists convert wet age-related macular degeneration patients away from monthly anti-VEGF injections toward refillable implant-based dosing. South Korea has become the fastest-growing single country, driven by rapid device regulatory adoption and an expanding specialist base. North America still commands the largest share of spending given its concentration of specialists and payers who first embraced these technologies. Sustained-release implants remain the second-fastest category.
Competitive character remains concentrated among a small group of large pharmaceutical and device manufacturers, evaluated consistently on a revenue basis across implants and platforms combined rather than on unit volume alone. Regulatory momentum favors the category directly: expanding label indications and new combination product approval pathways are pushing ophthalmologists toward device-based dosing well ahead of typical protocol revision cycles, a dynamic several smaller manufacturers have not priced in.
Market Definition
The ophthalmic combination product market covers sustained-release intravitreal implants, drug-eluting punctal plugs, drug-coated intraocular lenses, port delivery systems, bioerodible ocular inserts, and combination glaucoma drainage devices that integrate a therapeutic agent with a device delivery mechanism for ocular disease treatment. It excludes standalone ophthalmic pharmaceuticals administered without an integrated device component and excludes diagnostic imaging devices not incorporating drug delivery.
Base Year Value
$1.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
13.5% base case. Bull 15.0%. Bear 12.0%.
Fastest Growth Segment
Port Delivery Systems: 19.5% CAGR
Fastest Growth Country
South Korea: 15.9% CAGR
Fastest Growth Region
South Asia and Pacific: 15.6% CAGR
Largest Region
North America: 31% of 2025 global value
Market Leaders
AbbVie Inc., Genentech, Inc., Alcon Inc., Bausch + Lomb Corporation, EyePoint Pharmaceuticals, Inc. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Ophthalmic Combination Product Market Forecast Scenarios

ophthalmic-combination-product-market-size-forecast-scenario-1787304000847
Ophthalmic combination product adoption accelerated sharply between 2020 and 2025. Early sustained-release glaucoma implant approvals built initial clinical confidence, then port delivery system approval for wet age-related macular degeneration in 2021 opened a genuinely new treatment category, lifting historical growth to an estimated 12.0% compound rate. That acceleration outpaced most manufacturers' original commercial launch planning.
The base case assumes 13.5% annual growth through 2036, anchored on three mechanisms. First, expanding retina specialist adoption of refillable implant platforms keeps reducing injection burden for wet age-related macular degeneration and diabetic macular edema patients. Second, growing bioerodible glaucoma implant approvals keep converting daily eye drop regimens into single in-office procedures with months of sustained effect. Third, payer reimbursement recognition keeps catching up with clinical evidence, opening broader patient access across expanding coverage tiers.
A bull case builds if additional combination product indications expand faster than currently expected, pushing growth toward 15.0% as label expansions open new disease categories. The bear risk is reimbursement and manufacturing complexity: if payer coverage or device manufacturing scale-up lags clinical adoption, growth could slow well below expectations, capping growth near 12.0% across the forecast period.

From Monthly Injections to Durable Device Platforms

Ophthalmic combination products remain a genuinely early-stage category, but the market is undergoing a fast, durable shift as sustained-release implants and refillable delivery platforms convert chronic disease management from monthly office visits into a device-based treatment relationship. Clinical evidence still anchors adoption, but reimbursement recognition increasingly decides which manufacturer captures a specialist's long-term prescribing habit.
MARKET CONCENTRATION58% CR5Five manufacturers hold well over half of category revenue
AVERAGE SELLING PRICE$14,200 per implant procedureBlended price across implant, plug, and lens formats overall
LEADING APPLICATION SHARERetina disease, 47%One clinical application still dominates total procedure volume
INSTALLED BASE UTILISATION39%Approved platforms remain below their addressable patient capacity
REIMBURSEMENT COVERAGE RATE54% of eligible patientsPayer coverage still trails clinical guideline adoption in most markets
INPUT COST SHARE44% of unit COGSPolymer matrix and active pharmaceutical ingredient dominate cost
Manufacturers compete less on drug potency alone than on demonstrated device reliability and refill interval data, since retina and glaucoma specialists increasingly specify platforms with validated durability over therapies sold as a standalone pharmaceutical product. Manufacturing remains concentrated in the United States, Ireland, and Switzerland, while South Korea's domestic device and biotech sector is expanding rapidly to serve its own growing ophthalmology specialist base.
The next decade will be shaped by two forces pulling in the same direction: expanding label indications finally opening additional retina and glaucoma disease categories to device-based dosing, and payer reimbursement recognition catching up with clinical evidence built over the category's first launch cycles. Both push investment toward refillable and bioerodible platforms even as smaller practices weigh procedure cost against still-developing reimbursement clarity in several regional markets.
"Patients did not want a better drug. They wanted to stop coming in every month. That is the entire commercial thesis behind this category."
Director, Ophthalmic Devices and Combination Products Practice · MMA Medical Dev

Market Trends

Port Delivery Systems Reduce Injection Burden for Retina Disease

Refillable port delivery systems, surgically implanted devices that continuously release anti-VEGF therapy over six-month intervals, are converting wet age-related macular degeneration treatment from a monthly injection regimen into a twice-yearly office procedure, meaningfully reducing both patient burden and specialist chair time per treated eye. This is pushing retina specialists to requalify treatment protocols for appropriate patients well ahead of typical practice guideline cycles, since injection fatigue remains a leading cause of treatment discontinuation in real-world care. Manufacturers with validated refill safety and durability data are capturing disproportionate share of this conversion wave as evidence accumulates across major retina practices.
Market Impact: Adds 4.6 million eligible patients

Bioerodible Glaucoma Implants Replace Daily Eye Drop Regimens

Bioerodible intracameral implants that dissolve gradually while releasing glaucoma medication over several months are converting chronic glaucoma management from a daily eye drop regimen prone to poor patient adherence into a single in-office procedure with sustained intraocular pressure control. This is opening genuinely new procedure volume among glaucoma patients whose adherence to daily drop regimens has historically been poor enough to compromise treatment outcomes despite adequate drug availability. Manufacturers with validated sustained-release glaucoma implants are capturing disproportionate share of this adherence-driven conversion as more ophthalmologists adopt implant-first treatment protocols nationwide.
Market Impact: Compresses reimbursement timelines

Market Opportunities and Growth Drivers

Aging Population Expands Retina and Glaucoma Disease Prevalence

Wet age-related macular degeneration and glaucoma prevalence continue expanding across nearly every major market tracked in this report as populations age, driving growing baseline demand for treatment regardless of which specific device platform a specialist ultimately selects for a given patient. This demand base gives the category resilience that pure technology adoption trends alone would not provide, since disease prevalence keeps expanding even as treatment protocols shift toward device-based dosing across the industry. Manufacturers investing in broader label indications spanning multiple conditions are capturing disproportionate share of this expanding population as specialist familiarity builds nationwide.
Market Impact: Limits access to 43%

Specialist Reimbursement Advocacy Expands Payer Coverage

Retina and glaucoma specialty societies are actively publishing cost-effectiveness data demonstrating that device-based dosing reduces total treatment cost relative to monthly injection regimens once reduced office visit frequency and improved adherence outcomes are factored into payer coverage decisions. This is compressing the effective time between a combination product's regulatory approval and broad payer reimbursement recognition, converting what used to be a multi-year coverage negotiation into a faster adoption curve for newly approved platforms. Manufacturers investing directly in payer-facing health economics data are converting this advocacy into meaningfully faster reimbursement wins across major national and regional payer accounts.
Market Impact: Extends capacity scale-up by 14 mon

Market Restraints and Challenges

Surgical Implantation Requirement Limits Specialist Access

Port delivery systems and several sustained-release implants require surgical implantation rather than a simple office-based injection, creating genuine access friction for patients whose treating ophthalmologist lacks surgical retina training or whose local practice lacks the procedure infrastructure required for implantation and periodic refill visits. The root cause is that combination product platforms were designed around surgical retina specialist workflows rather than the broader base of comprehensive ophthalmologists who deliver most anti-VEGF injections today. Manufacturers are mitigating this by developing structured surgical training and proctoring programs, helping comprehensive ophthalmology practices build implantation competency without requiring a full surgical retina fellowship.
Market Impact: Adds 24% device-based dosing volume

Device Manufacturing Complexity Constrains Supply Scale-Up

Combination products require coordinated pharmaceutical and device manufacturing capability that few facilities possess simultaneously, creating genuine supply constraint as demand scales faster than manufacturers can validate additional production capacity under combination product regulatory requirements. The underlying cause is that regulatory approval for manufacturing changes in a combined drug-device product requires more extensive validation than either a standalone pharmaceutical or standalone device change would individually. Manufacturers are mitigating this by qualifying multiple manufacturing sites early in the product lifecycle and by building buffer inventory ahead of anticipated demand inflection points following major label expansions.
Market Impact: Adds 21% implant-based glaucoma vol
4 additional market trends, 3 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the market by product and technology type, the classification specialists and manufacturers use when specifying combination products and comparing platform capability across competing treatment decisions. This avoids blending upstream device engineering with the downstream clinical application categories that define how these products are actually prescribed across every major treatment decision made today.
ophthalmic-combination-product-market-market-share-analysis-1787304001484

Port Delivery Systems

Port delivery systems, surgically implanted refillable devices continuously releasing anti-VEGF therapy over extended intervals, remain the fastest-growing category as retina specialists convert appropriate wet age-related macular degeneration patients away from monthly injection regimens toward twice-yearly refill procedures. Growth concentrates wherever surgical retina training intersects with payer reimbursement recognition, particularly across North America and increasingly South Korea's rapidly expanding ophthalmology specialist base. Genentech has expanded port delivery system manufacturing capacity substantially, recognizing that validated refill safety data and surgical training infrastructure, not drug potency alone, decide which manufacturer captures a specialist's long-term treatment relationship. At a 19.5% forecast CAGR, roughly 1.4 times the market average, this segment is pulling capital investment toward refillable platform capacity faster than any other category.
CAGR 19.5%

Sustained-Release Intravitreal Implants

Sustained-release intravitreal implants, injectable or surgically placed devices releasing therapy over several months without requiring refill procedures, track specialist reimbursement advocacy expansion more directly than any other segment, making broad payer coverage a disproportionate growth driver for this category specifically. AbbVie and EyePoint Pharmaceuticals lead on installed clinical adoption, while newer entrants increasingly compete on extended dosing interval validation and workflow integration rather than device novelty alone. Demand here is tied more closely to reimbursement coverage expansion than to overall disease prevalence growth alone, since adoption depends heavily on payer recognition that varies by market and plan type. This segment's trajectory now depends heavily on how quickly extended dosing interval data expands across additional indications.
CAGR 16.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America commands the largest share of spending given its concentration of the specialists who first embraced these technologies, while South Korea's regulatory adoption and East Asia's expanding specialist base anchor the fastest-growing pipelines. Western Europe and Latin America contribute steady, gradually expanding demand of their own.

North America

The United States anchors regional demand through its dense concentration of academic retina and glaucoma specialty centers that pioneered combination product clinical trials and continue driving broad early commercial adoption. Canada contributes a smaller, steadily growing demand base benefiting from proximity to the same manufacturer clinical relationships and continuing medical education programs shared across the region. The region's regulatory pathway leadership and largest concentration of surgical retina specialists give it durable commercial primacy even as unit growth moderates relative to faster-growing emerging markets. Growth stays healthy but trails East Asia and South Asia and Pacific because the region's leading academic centers have already completed much of their initial adoption, and Mexico's referral relationships add further steady momentum.
Share: 31% | CAGR: 13.0% (2026 to 2036)

Western Europe

Germany anchors both regional clinical trial depth and commercial adoption, home to leading ophthalmology research centers and specialists whose early combination product studies shaped current European treatment guideline recommendations. France and the United Kingdom follow with steady demand tied to national health systems increasingly recognizing sustained-release implants as reimbursable standard practice. Regulatory pressure compounds adoption directly: European Medicines Agency approval pathways and national reimbursement bodies are pushing broader combination product access ahead of most other global markets tracked in this report. Growth trails East Asia and South Asia and Pacific because the region's mature specialist base is expanding volume more slowly than newer entrants, and Italy and Spain add smaller, steadily growing demand of their own.
Share: 22% | CAGR: 11.9% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
ophthalmic-combination-product-market-country-cagr-analysis-1787304002271

Where Combination Product Manufacturers Actually Capture Margin

Standard implant sales increasingly compete on clinical data alone as more manufacturers enter the category, so the companies protecting margin monetize the training and support layer: surgical proctoring, payer advocacy, and long-term supply agreements. The four levers below reflect where MMA's interviews with specialty practice procurement teams show real, sustained willingness to pay a premium across every major decision.

Surgical Training and Proctoring Program Licensing

Manufacturers increasingly bundle structured surgical training and remote proctoring support alongside device supply agreements rather than selling implants as a standalone pharmaceutical purchase, since implantation competency and refill technique meaningfully affect patient outcomes and continued specialist prescribing confidence. Manufacturers offering integrated training programs capture meaningfully higher lifetime account value than device-only suppliers, worth roughly 28% more per specialist relationship over a multi-year adoption curve, since training investment builds procedural loyalty that pure clinical data cannot replicate on its own. Adoption of these bundled training programs continues accelerating as more comprehensive ophthalmology practices add surgical implantation capability.
Market Impact: Adds 28 percent higher lifetime acc

Payer Health Economics and Advocacy Support Services

Manufacturers increasingly fund dedicated payer-facing health economics teams that build cost-effectiveness cases for combination products directly with major national and regional payers, converting what used to be a slow, practice-by-practice reimbursement negotiation into a faster, centrally coordinated coverage expansion process across their accounts. This is becoming the primary differentiator in specialist adoption speed, where practices increasingly select manufacturers based on reimbursement support depth rather than clinical data alone, and MMA interviews suggest manufacturers with dedicated payer advocacy teams capture roughly 25% faster reimbursement recognition across the category overall today across most accounts served.
Market Impact: Adds 25 percent faster reimbursemen

Long-Term Device and Refill Supply Agreements

Large retina and glaucoma practices increasingly sign multi-year device and refill supply agreements guaranteeing consistent product availability and predictable per-procedure pricing throughout an extended treatment relationship, converting what used to be a series of individual purchase orders into predictable recurring revenue worth roughly 23% of a manufacturer's forward account revenue across the agreement term. Manufacturers offering these agreements gain visibility into future refill demand that supports continued manufacturing investment, while practices gain protection against supply shortages and pricing volatility on devices purchased at high recurring volume each cycle across their facilities.
Market Impact: Locks in refill revenue for 4 to 6

Practice Workflow Integration and Support Services

Manufacturers offering integrated practice management support, including refill scheduling coordination and patient adherence tracking tools, capture recurring service revenue while simultaneously deepening customer relationships that make competitive displacement more difficult for rivals without comparable practice support infrastructure available today across the category. For practices scaling combination product treatment volume, the value proposition is reduced administrative burden without separate scheduling and tracking system procurement processes across multiple locations and specialties. Early adopters report workflow integration attach rates approaching 26% among first-time combination product practices, growing steadily each year across the broader category.
Market Impact: Reaches nearly 26 percent integrati

Who Controls the Margin Pool

CR5 sits at 58%, reflecting a category meaningfully concentrated among a small group of large manufacturers, evaluated here on a revenue basis across implants, delivery platforms, and coated devices combined. AbbVie and Genentech lead on category revenue scale, with a meaningful gap separating them from smaller challengers, including Alcon and Bausch + Lomb, each strong in specific segments rather than universally. Smaller manufacturers increasingly struggle to match clinical trial investment la
Current activity centers on three dimensions: surgical training and proctoring program depth, payer health economics and advocacy investment, and long-term device supply agreement structuring for large specialty practice groups. Manufacturers lacking refillable platform capability are increasingly partnering with device specialists rather than losing specialist adoption on missing-technology grounds alone across the industry.

Emerging pressure comes from smaller biotech manufacturers advancing next-generation bioerodible and gene-therapy-adjacent delivery platforms that could reduce refill frequency even further than current combination products achieve. If these smaller manufacturers continue converting clinical trial success into commercial approval, expect rankings among the next several challengers to shift by 2030, as novel platforms displace slower-moving incumbents across specific disease indications. Established leaders have limited time to respond before meaningful share shifts occur.
ophthalmic-combination-product-market-company-positioning-matrix-1787304002838

Competitive Moat and Risk Dimensions

ABBVIE INC.

Moat: Broad Glaucoma Franchise Depth

AbbVie's broad, established glaucoma pharmaceutical franchise gives it specialist relationship depth and commercial infrastructure that narrower combination product entrants cannot easily replicate across a practice's full treatment portfolio. That combined franchise breadth makes AbbVie a default vendor for glaucoma specialists seeking a single integrated treatment relationship.
ABBVIE INC.

Risk: Retina Platform Competitive Gap

AbbVie's glaucoma-centric combination product portfolio leaves it more exposed than retina-focused competitors to specialists seeking integrated wet age-related macular degeneration treatment platforms specifically. Closing this gap requires either sustained capital investment in retina delivery technology or acquisition of specialized retina platform developers with established clinical evidence.
GENENTECH, INC.

Moat: First-Mover Port Delivery Scale

Genentech's first-mover position in port delivery system approval and commercialization gives it surgical training infrastructure and refill safety data depth that newer entrants cannot quickly replicate regardless of technical sophistication invested. That accumulated clinical and training relationship increasingly functions as a competitive moat for specialist adoption decisions specifically.
GENENTECH, INC.

Risk: Manufacturing Scale-Up Constraint Exposure

Genentech's port delivery system faces genuine manufacturing complexity that has constrained supply scale-up relative to specialist demand, leaving it more exposed than simpler combination product competitors to capacity-driven adoption delays across major markets. Managing this requires sustained manufacturing investment competing against continued core platform development priorities and research spending.

Players Tracked

Prominent Players

AbbVie Inc.
Genentech, Inc.
Alcon Inc.
Bausch + Lomb Corporation
EyePoint Pharmaceuticals, Inc.

Other Key Players

Ocular Therapeutix, Inc.
Graybug Vision, Inc.
Kodiak Sciences Inc.
Regeneron Pharmaceuticals, Inc.
Novartis AG
Santen Pharmaceutical Co., Ltd.
Ocumension Therapeutics
Sun Pharmaceutical Industries Ltd.
Harrow, Inc.
Mati Therapeutics Inc.
Envisia Therapeutics Inc.
PolyActiva Pty Ltd
Nicox S.A.
Clearside Biomedical, Inc.
Formycon AG

Recent Developments

APRIL 2025

Genentech Expands Port Delivery System Manufacturing Capacity

Genentech announced expanded manufacturing capacity for its refillable port delivery system at an existing North American facility, addressing supply constraints that had limited new patient starts across several major retina practice networks. The expansion targets specialists seeking broader patient access ahead of anticipated additional label expansion this year.
Signal: Signals Genentech prioritizing supply scal
AUGUST 2025

AbbVie Launches Expanded Glaucoma Implant Training Program

AbbVie announced the commercial launch of an expanded surgical training and proctoring program for its sustained-release glaucoma implant, targeting comprehensive ophthalmology practices seeking implantation competency without full surgical retina fellowship training. The launch follows favorable adoption data shared with several major specialty practice groups this year.
Signal: Signals AbbVie prioritizing practice-level
DECEMBER 2025

EyePoint Pharmaceuticals Signs Distribution Agreement With Regional Practice Network

EyePoint Pharmaceuticals signed a multi-year distribution agreement with a major regional retina specialty practice network, securing preferred-supplier status for its sustained-release implant platform ahead of continued specialist adoption growth. The agreement covers device supply and training access across the network's growing practice portfolio nationwide this year.
Signal: Signals mid-sized manufacturers actively p

Polymer Matrix and API Manufacturing Costs

Polymer matrix materials and active pharmaceutical ingredient synthesis together account for roughly 44% of combination product cost of goods sold, making these inputs the dominant cost driver in the category ahead of general device assembly and sterile packaging labor. Polymer and API costs vary substantially by formulation complexity, with sustained-release engineering and pharmaceutical-grade purity requirements driving most of the cost variability manufacturers face.
Specialty polymer costs spiked through 2023 as broader pharmaceutical and medical device demand absorbed available specialized fabrication capacity faster than new capacity could be added, according to company disclosures citing constrained sustained-release polymer availability across multiple suppliers. Manufacturers without long-term polymer supply agreements or in-house formulation capability saw costs rise faster than they could pass through to fixed reimbursement pricing negotiated before the spike occurred across the industry.

Smaller manufacturers without established polymer sourcing relationships or long-term supply agreements absorb input cost volatility directly into thin margins, while larger players like AbbVie and Genentech use existing pharmaceutical supply chain relationships to insulate margins from formulation cost swings. Manufacturers newly entering the category without comparable established supply relationships carry meaningfully greater cost exposure than incumbents who capture more of the value chain themselves across the broader category.
ophthalmic-combination-product-market-cost-volatility-analysis-1787304003044

Long-Term Polymer and API Supply Agreements

The largest manufacturers are locking multi-year specialty polymer and active ingredient supply agreements directly with formulation partners rather than competing for spot capacity, securing priority access and more predictable pricing across major production programs and forecast cycles ahead, reinforcing the scale advantages already present across the category and its narrow overall specialty supply base.

Vertical Integration Into Sustained-Release Formulation

Larger manufacturers are investing directly in in-house sustained-release polymer formulation capability rather than relying entirely on third-party specialty suppliers, capturing more of the value chain and reducing exposure to formulation cost swings across the category's highest-volume implant lines. This trend continues strengthening steadily as demand for validated sustained-release platforms keeps expanding across every major regional market tracked.

Manufacturing Site Diversification Strategies

Manufacturers are diversifying polymer and API sourcing and validating multiple manufacturing sites rather than depending on a single facility, reducing exposure to specific production disruptions that have affected particular combination product categories during recent volatility episodes across markets. This diversification has become standard practice among the category's larger manufacturers over the past several regulatory cycles industry-wide.

Portfolio Architecture for Margin Defence

MMA's tier architecture separates the category into three margin bands. Volume and commodity-adjacent standard single-indication implants compete on price against widely available generic-adjacent formulations and carry thin margin, premium and certified refillable and multi-indication platforms carry higher margin on documented durability evidence and reimbursement recognition, and sustainability-linked next-generation formulations, including gene-therapy-adjacent and multi-year sustained-relea
The tension between volume and premium plays out most visibly among mid-sized specialty practices, who want refillable platform capability at closer to standard implant pricing. That up-tier migration remains slow given how many mid-sized practices still evaluate procedure economics cautiously before committing further capital investment. Manufacturers that fail to bundle training and reimbursement support services risk losing share to more capable rivals.

High-value margin pools concentrate in large specialty practice group agreements bundled with surgical training, payer advocacy, and long-term supply agreements, where recurring service and reimbursement-support-attach revenue increasingly outweighs the margin earned on any individual procedure sale alone. That concentration is pulling investment steadily toward training capability and payer coordination rather than incremental manufacturing capacity expansion alone across the category.

Volume / Commodity-Adjacent Tier

Standard single-indication implants sold primarily on clinical data against a narrowing set of comparable formulations, serving cost-sensitive practices where gross margin stays moderate and competition is driven increasingly by reimbursement negotiation.
Gross Margin: 24%-29%

Premium / Certified Tier

Refillable and multi-indication platforms specified by practices requiring documented durability evidence, training infrastructure, and long-term supply agreements, commanding meaningfully higher margin on demonstrated performance achieved across every major procurement market worldwide today.
Gross Margin: 38%-44%

Sustainability / Regulatory / Next-Generation Tier

Gene-therapy-adjacent and multi-year sustained-release platforms positioned for practices chasing broader indication coverage and dramatically reduced treatment burden, where regulatory approval depth and clinical evidence support the category's highest margin overall across most major markets today.
Gross Margin: 48%-56%
ophthalmic-combination-product-market-portfolio-architecture-1787304003552

Specialist Prescribing and Reimbursement Economics

A device sale is rarely a single transaction for the largest specialty practice group accounts. Surgical training, payer advocacy support, and long-term supply agreements convert what used to be a one-time procedure purchase into a relationship spanning years of ongoing refill and follow-up procedures. Manufacturers that capture the training and reimbursement-support attachment at first sale retain more lifetime value per account than those competing on clinical data alone.
Adoption depth varies sharply by practice type. Large academic and specialty retina groups convert fastest and most completely, standardizing entire treatment protocols onto certified, proven platforms once surgical training and reimbursement clarity align, making them the highest-value account type despite competitive pricing negotiated across the relationship. Smaller comprehensive ophthalmology practices convert more slowly, often relying on referral relationships with specialty centers for years before adopting in-house implantation capability directly.

A generational shift in specialists is compounding the reimbursement-driven shift. Younger ophthalmologists entering practice increasingly expect device-based, extended-dosing treatment as standard protocol, a training expectation an older generation of specialists, who trained primarily on monthly injection-first regimens, rarely required as rigorously. That shift is accelerating premium-tier adoption even among practices that have not yet faced direct competitive pressure from device-adopting rivals nearby.
ophthalmic-combination-product-market-end-use-penetration-index-1787304004054

What Matters Most Through 2036

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / REFILLABLE PLATFORM INVESTMENT

Scale refillable manufacturing capacity ahead of the next demand wave

Refillable platform demand continues outpacing manufacturing capacity across the category, and manufacturers that scale supply ahead of demand are already capturing disproportionate share of new patient starts ahead of competitors still constrained by capacity limitations. Manufacturers that invest in manufacturing scale-up now will secure preferred-vendor status with major specialty practice groups before competitors catch up on the capital investment required. Continuing to treat manufacturing capacity as a secondary concern risks ceding the fastest-growing, most differentiated segment to competitors already solving the supply constraint.
02 / PAYER ADVOCACY DEPTH

Deepen payer health economics investment ahead of the next coverage cycle

Reimbursement recognition increasingly decides adoption speed as much as clinical data itself, and manufacturers that deepen validated payer advocacy pathways will capture disproportionate share of specialist prescribing as practices seek reimbursement confidence without full financial risk. Manufacturers that invest in rigorous, validated health economics data now will build switching costs that protect prescribing relationships better than competitors relying on clinical data alone. This advocacy investment requires sustained spending across multiple years before any single coverage cycle fully rewards that patient positioning choice.
03 / RECURRING TRAINING REVENUE CAPTURE

Bundle training and advocacy into every large specialty practice agreement

Surgical training support and long-term supply agreements already generate meaningfully higher recurring revenue than standard device sales, yet many manufacturers still sell these as separate negotiations rather than a default part of every agreement presented to large specialty practice buyers. Manufacturers that make training and advocacy attachment the default, requiring buyers to actively opt out rather than opt in, will capture materially more lifetime value per account than competitors treating these services as an afterthought entirely. This remains underexploited by nearly every manufacturer outside the two largest players active today.
04 / NEXT-GENERATION PLATFORM COMPETITION

Invest in extended-dosing research ahead of continued biotech disruption

Smaller biotech manufacturers continue advancing next-generation bioerodible and gene-therapy-adjacent platforms that could reduce refill frequency even further, and incumbents overly dependent on current-generation combination products face real competitive displacement risk across the forecast period covered in this report. Manufacturers that invest in next-generation extended-dosing research now, rather than defending current platform economics alone, will protect long-term share better than competitors continuing to rely primarily on first-generation combination product advantages. This repositioning requires sustained research investment well before disruptive platforms fully mature in the clinic.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Ophthalmic Combination Product Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Ophthalmic Combination Product Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a multi-site retina specialty practice group operating 11 offices across four states, with a large existing wet age-related macular degeneration patient population and a stated goal of evaluating refillable port delivery system adoption across its highest-volume offices. Annual treatment procedure volume exceeds 38,000 injections (client-reported, unverified by MMA), concentrated primarily across anti-VEGF therapy and emerging device-based platform evaluation nationwide.
STRATEGIC CHALLENGE
The client faced a capital and training allocation decision balancing port delivery system adoption against surgical training capacity constraints and uncertain reimbursement recognition across its diverse regional payer mix. Leadership needed a structured evaluation framework weighing reduced injection burden benefits against training investment and payer coverage uncertainty across its multi-state footprint.
MMA APPROACH
MMA conducted a structured evaluation of the client's patient population against port delivery system eligibility criteria and reimbursement coverage data across its payer mix, benchmarked vendor-reported refill safety claims against MMA's proprietary combination product performance database, and facilitated reference site visits with comparable retina practice groups. The engagement combined primary interviews with practicing retina specialists alongside independent reimbursement data verification across multiple facility types.
KEY FINDINGS
  1. Four of the client's eleven offices lacked surgical retina specialists with sufficient training capacity to support planned port delivery system adoption within the original rollout timeline.
  2. The client's payer mix showed meaningfully higher reimbursement recognition for port delivery procedures than for several competing sustained-release alternatives across its service area.
  3. Prioritizing port delivery system rollout at eligible offices first reduced projected annual injection visit volume by an estimated 31%, per MMA's model.
  4. Reimbursement variation across the client's regional payer mix emerged as a meaningfully underestimated financial planning risk factor requiring further detailed analysis before rollout.
CLIENT PROFILE
The client is a multi-site retina specialty practice group operating 11 offices across four states, with a large existing wet age-related macular degeneration patient population and a stated goal of evaluating refillable port delivery system adoption across its highest-volume offices. Annual treatment procedure volume exceeds 38,000 injections (client-reported, unverified by MMA), concentrated primarily across anti-VEGF therapy and emerging device-based platform evaluation nationwide.
STRATEGIC CHALLENGE
The client faced a capital and training allocation decision balancing port delivery system adoption against surgical training capacity constraints and uncertain reimbursement recognition across its diverse regional payer mix. Leadership needed a structured evaluation framework weighing reduced injection burden benefits against training investment and payer coverage uncertainty across its multi-state footprint.
MMA APPROACH
MMA conducted a structured evaluation of the client's patient population against port delivery system eligibility criteria and reimbursement coverage data across its payer mix, benchmarked vendor-reported refill safety claims against MMA's proprietary combination product performance database, and facilitated reference site visits with comparable retina practice groups. The engagement combined primary interviews with practicing retina specialists alongside independent reimbursement data verification across multiple facility types.
KEY FINDINGS
  1. Four of the client's eleven offices lacked surgical retina specialists with sufficient training capacity to support planned port delivery system adoption within the original rollout timeline.
  2. The client's payer mix showed meaningfully higher reimbursement recognition for port delivery procedures than for several competing sustained-release alternatives across its service area.
  3. Prioritizing port delivery system rollout at eligible offices first reduced projected annual injection visit volume by an estimated 31%, per MMA's model.
  4. Reimbursement variation across the client's regional payer mix emerged as a meaningfully underestimated financial planning risk factor requiring further detailed analysis before rollout.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 4): Complete office-level readiness assessment and prioritize port delivery adoption at the four best-positioned offices. Phase 2: Phase 2 (Months 5 to 11): Deploy structured surgical training while tracking refill safety and patient outcomes against baseline injection metrics. Phase 3: Phase 3 (Months 12 to 20): Expand adoption across remaining offices pending validated results from the initial deployment phase completed earlier.
OUTCOME
The client's first four offices achieved measurable reductions in injection visit volume and reported improved patient satisfaction within seven months of deployment completion (client-reported, unverified by MMA), supporting the phased expansion plan that had originally motivated the readiness assessment engagement. The remaining seven offices are scheduled for phased adoption over the following twenty months.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Ophthalmic Combination Product Market?

MMA estimates the global ophthalmic combination product market at $1.8 billion in 2025. Growth concentrates in port delivery systems and sustained-release implants, driven by injection burden reduction and expanding reimbursement recognition.

How large will the Ophthalmic Combination Product Market be by 2036?

MMA forecasts the market reaching $7.24 billion by 2036, up from $2.04 billion in 2026. That represents roughly a 3.55 times expansion over the full ten-year forecast period covered.

What is the CAGR for the Ophthalmic Combination Product Market 2026 to 2036?

MMA's base case forecasts a 13.5% compound annual growth rate, with a bull case of 15.0% and a bear case of 12.0% depending on reimbursement and manufacturing scale-up timing.

Which segment is growing fastest?

Port delivery systems lead at a 19.5% CAGR, roughly 1.4 times the overall market rate, as retina specialists convert eligible patients away from monthly injection regimens toward refillable implant dosing.

Who are the major companies in the Ophthalmic Combination Product Market?

AbbVie, Genentech, Alcon, Bausch + Lomb, and EyePoint Pharmaceuticals lead the category, together holding an estimated 58% combined share on a revenue basis worldwide across implants and platforms.

Which country is growing fastest?

South Korea leads at an estimated 15.9% CAGR, outpacing the global average as rapid regulatory adoption and an expanding ophthalmology specialist base continue growing faster than any comparable economy.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Product and Technology Type

  • Sustained-Release Intravitreal Implants
  • Drug-Eluting Punctal Plugs
  • Drug-Coated Intraocular Lenses
  • Port Delivery Systems
  • Bioerodible Ocular Inserts
  • Combination Glaucoma Drainage Devices

By End-Use Application

  • Wet Age-Related Macular Degeneration
  • Diabetic Macular Edema
  • Glaucoma and Ocular Hypertension
  • Post-Surgical and Dry Eye Management

By Commercial Dimension

  • Direct Specialty Practice Procurement
  • Academic Medical Center Agreements
  • Long-Term Device Supply Contracts
  • Payer-Negotiated Coverage Channels

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The ophthalmic combination product market covers sustained-release intravitreal implants, drug-eluting punctal plugs, drug-coated intraocular lenses, port delivery systems, bioerodible ocular inserts, and combination glaucoma drainage devices that integrate a therapeutic agent with a device delivery mechanism for ocular disease treatment. It excludes standalone ophthalmic pharmaceuticals administered without an integrated device component and excludes diagnostic imaging devices not incorporating drug delivery.
Quantitative Units
USD billions (current prices); annual treated patient volume and procedure counts where applicable
Segmentation Dimensions
By Product and Technology Type; By End-Use Application; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Singapore, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, and additional markets relevant to this sector
Key Companies Profiled
AbbVie Inc., Genentech, Inc., Alcon Inc., Bausch + Lomb Corporation, EyePoint Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Graybug Vision, Inc., Kodiak Sciences Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., Ocumension Therapeutics, Sun Pharmaceutical Industries Ltd., Harrow, Inc., Mati Therapeutics Inc., Envisia Therapeutics Inc., PolyActiva Pty Ltd, Nicox S.A., Clearside Biomedical, Inc., Formycon AG
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-106
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Ophthalmic Combination Product Market Report (2026 to 2036).

The full Ophthalmic Combination Product Market report delivers granular five-year and ten-year forecasts across all six product segments, specialist adoption tracking by region, and manufacturer benchmarking drawn from MMA's proprietary combination product performance database. It includes detailed profiles of all twenty companies covered here, extended regional analysis across every major treatment market, and a regulatory tracker spanning label expansions and reimbursement coverage decisions. Subscribers receive quarterly data refreshes through the full forecast period. Buyers also gain direct analyst access for engagement-specific questions throughout the subscription term.
Reimbursement coverage tracker by region and payer
Ten-year segment-level forecasts across all product types
Manufacturer benchmarking data across platforms and pricing
Label expansion and regulatory tracking module
Twenty-company competitive profiles with moat analysis
Quarterly data refresh access throughout subscription

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts